Bitolterol

Bitolterol

Bitolterol is a bronchodilator used for the treatment of asthma. It is a prodrug of colterol, and is activated by esterases in the lungs after inhalation. Bitolterol is marketed under the brand name Tornalate.

Pharmacology

Bitolterol is a beta-2 adrenergic receptor agonist, meaning it works by relaxing the smooth muscles in the airways, allowing them to open up and make it easier to breathe. This makes it effective in treating conditions like asthma and chronic obstructive pulmonary disease (COPD), where the airways become constricted and inflamed.

Bitolterol is a prodrug, which means it is inactive until it is metabolized in the body. In the case of bitolterol, it is metabolized by esterases in the lungs into its active form, colterol. This means that the drug is activated directly in the lungs, where it is needed, reducing the risk of systemic side effects.

Usage

Bitolterol is typically administered via inhalation, using a metered dose inhaler. The usual dosage is two inhalations every 4 to 6 hours. However, the exact dosage may vary depending on the individual patient's condition and response to the medication.

Side Effects

Like other beta-2 adrenergic receptor agonists, bitolterol can cause side effects. These may include tachycardia (rapid heart rate), palpitations, tremor, and nervousness. More serious side effects can include cardiac arrhythmias and hypokalemia (low potassium levels).

History

Bitolterol was first approved by the Food and Drug Administration (FDA) in 1984. It was marketed under the brand name Tornalate by Ciba-Geigy, but has since been discontinued.

See Also

• Bronchodilator
• Beta-2 adrenergic receptor
• Asthma
• Chronic obstructive pulmonary disease

‎